Translational Cancer Research

Program in Translational Research comprises a mix of basic and clinical scientists who apply their combined skills to do bench to bedside to bench research. This research paradigm has the greatest probability of generating new therapeutic approaches in the treatment of cancer. Research efforts include investigator initiated clinical trials. The translational research group investigators are working with an array of solid tumor model systems to understand the molecular events that drive, and are critical for tumor progression and metastasis, and resistance to therapy. Organ cites under investigation are neoplasms of the: bladder, breast, head and neck, kidney, lung, ovary, pancreas and prostate. The basic science studies focus on identifying signal transduction targets, critical molecular pathways that are distinct in various tumor types. Preclinical and clinical studies focus on developing therapeutic interventions, and diagnostic markers to distinguish indolent vs. aggressive disease. The long-term goals of this group are to identify novel targets that are critical for solid tumor progression and metastasis. The underlying hypothesis that the group is collectively testing is that despite distinct origins, there are common targets among various solid tumor malignancies that could be explored to prevent tumor progression, tumor metastasis and therapeutic resistance. The mission of this group is to share knowledge, agents and resources to facilitate ongoing research projects, to facilitate community outreach and education, and to provide an interdisciplinary working group to formulate new approaches to diagnosis and treatment of solid tumors.